None listed
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Atrimed Pharmaceuticals Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1)Both male and female adult populations aged from 18 to 60 years with or without background co-morbidities 2)Convalescent, Rapid antigen test (RAT) negative for SARS-CoV2, IgG positive or negative, vaccinated for SARS CoV2 3) Unexposed, Rapid antigen test (RAT) negative for SARS-CoV2, IgG positive or negative, vaccinated either with COVAXIN or COVISHIELD for SARS CoV2 4) Volunteer is willing and able to comply with all the trial requirements 5) All volunteers obtained written informed consent form in English as well as native language, Kannada
Exclusion criteria
Exclusion criteria: 1) Patients with active COVID-19 infection (RAT positive) 2) Known patients of HIV, Hepatitis-B/C, H1N1 3) Pregnant and lactating women 4) Patients with known autoimmune diseases on immunosuppressants and steroids 5) Patients who have participated in another clinical trial within the previous 30 days 6) Patient not willing to give informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of who has protective immunity against OMICRON variant of SARS-CoV-2 irrespective of IgG and vaccine status.Timepoint: Within 1 week of negative COVID19 rapid antigen test | — |
Secondary
| Measure | Time frame |
|---|---|
| It will enable prioritised vaccination of susceptible populationTimepoint: Within 1 week of negative COVID19 rapid antigen test | — |
Countries
India
Contacts
Public ContactDr Hrishikesh Damle
Immunitas Biosciences Pvt. Ltd.
Outcome results
None listed